Researchers have demonstrated a promising new approach to delivering immunotherapy agents to fight cancer. The approach involves tethering an immunotherapy agent called a STING agonist to an acid ...

Synthetic CDN STING agonist, intratumoral injection alone or with anti-PD1: Phase I clinical trial: Merck & Co. Synthetic CDN STING agonist, IT injection alone or with anti-PD1 (Keytruda: ...

GSK revealed the STING agonist cull in its third-quarter earnings (PDF) presentation, where the company also disclosed that two other candidates have been removed from its phase 1 pipeline. One of ...

Several STING agonists have demonstrated antitumor efficacy in preclinical studies and are currently under clinical development. However, systemic administration of STING agonists may have adverse ...

Amid high expectations, the first clinical data with Merck & Co’s STING agonist at ESMO has proved a disappointment—at least as a monotherapy. The preliminary results from the phase 1 trial ...

TORONTO, April 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing i ...

In mice bearing prostate or pancreas cancer tumors, the effects of STING agonist treatment on tracer uptake, T-lymphocyte activation marker levels, and tumor growth were evaluated.

Furthermore, the STING agonist activated immune cells in both tumours and lymph nodes, thereby remodelling the immune microenvironment. Nature Reviews Drug Discovery 24 , 249 (2025) doi: https ...

SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United ...

In a pair of studies, researchers report the discovery and molecular pharmacology of stable, synthetic STING (stimulator of interferon genes) agonists that induce anticancer immune responses in mice.

In vitro, the STING and TLR agonists both triggered cytokine release, changed the expression of the Fcg receptors, and boosted the ability of rituximab to engulf the tumor cell.